Simplified Maintenance Therapy with Abacavir/Lamivudine/Zidovudine plus Tenofovir After Sustained HIV Load Suppression: Four Years of Follow-up

REFERENCES

• Paterson DL, Swindells S, Mohr J, et al. Adherence to pro-tease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• Kerr T, Walsh J, Lloyd-Smith E, et al. Measuring adherence to highly active antiretroviral therapy: implications for re-search and practice. Curr HIV/AIDS Rep. 2005;2: 200–205.
   PubMedGoogle Scholar
• Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62.
   PubMed Web of Science ®Google Scholar
• Duran S, Saves M, Spire B, et al., for APROCO Study Group. Failure to maintain long-term adherence to highly active antiretroviral therapy: the role of lipodystrophy. AIDS. 200115: 2441–2444.
   Google Scholar
• Bucher HC, Young J, Battegay M. Protease inhibitor-sparing simplified maintenance therapy: a need for per-spective. J Antimicrob Chemother 2004;54: 303–305.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Ravasio L, et al. Outcome of 2 simplification strategies for the treatment of human im-munodeficiency virus type 1 infection. Clin Infect Dis. 2005;37:41–49.
   Web of Science ®Google Scholar
• Martinez E, Arnaiz JA, Podzamczer D, et al. Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection. N Engl J Med. 2003;349:1036–1046.
   PubMed Web of Science ®Google Scholar
• Gil P, de Gorgolas M, Estrada V, et al. Long-term efficacy and safety of protease inhibitor switching to nevirapine in HIV-infected patients with undetectable virus load. Clin In-fect Dis. 2004;39:1024–1029.
   PubMed Web of Science ®Google Scholar
• Katlama C, Fenske S, Gazzard B, et al., on behalf of the AZL30002 European Study Team. TRIZAL study: switching from successful HAART to Trizivir (abacavir-lamivudine-zidovudine combination tablet): 48 weeks efficacy, safety and adherence results. HIV Med. 2003;4: 79–86.
   PubMedGoogle Scholar
• Opravil M, Hirschel B, Lazzarin A, et al., for the Swiss HIV Cohort Study. A randomized trial of simplified mainte-nance therapy with abacavir, lamivudine, and zidovudine in human immunodeficiency virus infection. J Infect Dis. 2002;185: 1251–1260.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Ripamonti D, Suter F Switch strategies in patients on effective HAART. J Antimicrob Chemother 2005;55(6):821–823.
   PubMed Web of Science ®Google Scholar
• Opravil M, Baumann D, Chave JP, et al., for Swiss HIV Co-hort Study. Long-term efficacy after switch from protease inhibitor-containing highly active antiretroviral therapy to abacavir, lamivudine, and zidovudine. AIDS. 2004;18: 2213–2215.
   PubMed Web of Science ®Google Scholar
• d'Ettorre G, Mastroianni CM, Massetti AP, et al. Switching from protease inhibitors to a single-class regimen of aba-cavir/lamivudine/zidovudine plus tenofovir in patients with HIV load suppression. AIDS. 2005;19: 841–842.
   PubMed Web of Science ®Google Scholar
• Latham V, Stebbing J, Mandalia S, et al. Adherence to trizivir and tenofovir as a simplified salvage regimen is associated with suppression of viraemia and a decreased cholesterol. J Antimicrob Chemother 2005; 56:186–189.
   PubMed Web of Science ®Google Scholar
• Moyle G, Higgs C, Teague A, et al. An open-label, random-ized comparative pilot study of a single-class quadruple therapy regimen versus a 2-class triple therapy regimen for individuals initiating antiretroviral therapy. Antivir Ther 2006;11:73–78.
   PubMed Web of Science ®Google Scholar
• Mastroianni CM, d'Ettorre G, Vullo V. Evolving simplified treatment strategies for HIV infection: the role of a single- class quadruple-nucleoside/nucleotide regimen of trizivir and tenofovir. Expert Opin Pharmacother 2006;7: 2233–2241.
   Google Scholar
• Gulick RM, Lalama CM, Ribaudo HJ, et al. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression. AIDS. 2007;21:813–823.
   PubMed Web of Science ®Google Scholar
• Kostrikis LG, Touloumi G, Karanicolas R, et al. The Mul-ticenter Hemophilia Cohort Study Group. Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA load. J Virol. 2002;76: 10099–10108.
   PubMed Web of Science ®Google Scholar
• Andreoni M, Parisi SG, Sarmati L, et al. Cellular proviral HIV DNA decline and viral isolation in naive subjects with <5000 copies of hiv rna and >500 CD4 cells treated with highly active antiretroviral therapy. AIDS. 2000;14:23–29.
   PubMed Web of Science ®Google Scholar
• Pellegrin I, Caumont A, Garrigue I, et al. Predictive value of provirus load and DNA human immunodeficiency virus genotype for successful abacavir-based simplified therapy. J Infect Dis. 2003;187:38–46.
   PubMed Web of Science ®Google Scholar
• Viard JP, Burgard M, Hubert JB, et al. Impact of 5 years of maximally successful highly active antiretroviral therapy on CD4 cell count and HIV-1 DNA level. AIDS. 2004;18:45–49.
   PubMed Web of Science ®Google Scholar
• Elion R, Cohen C, DeJesus E, et al., for C0L40263 Study Team. Once-daily abacavir/lamivudine/zidovudine plus tenofovir for the treatment of HIV-1 infection in antiretroviral-naive subjects: a 48-week pilot study. HIV Clin Trials. 2006;7: 324–333.
   PubMed Web of Science ®Google Scholar
• Greiger-Zanlungo P, Blick G., Rubin D, et al. Quadruple nucleoside reverse transcriptase inhibitor (NRTI) therapy with trizivir (TZV) and viread (TDF) in naive and experienced HIV/AIDS patients: A 30-month follow-up. In: Program andabstracts of the 10th European AIDS Conference/EACS; November 17–20, 2005; Dublin, Ireland. Abstract PE7.5/9.
   Google Scholar
• Rouzioux C, Hubert JB, Burgard M, et al. SEROCO Cohort Study Group. Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression in-dependently of HIV-1 RNA levels and CD4+ T cell counts. J Infect Dis. 2005;192:46–55.
   Google Scholar
• Goujard C, Bonarek M, Meyer L, et al. Agence Nationale de Recherche sur le Sida PRIMO Study Group. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis. 2006;42:709–715.
   Google Scholar
• Sarmati L, Parisi SG, Nicastri E, et al. Association be-tween cellular human immunodeficiency virus DNA level and immunological parameters in patients with undetect-able plasma viremia level during highly active antiretroviral therapy. J Clin Microbiol. 2005;43:6183–6185.
   PubMed Web of Science ®Google Scholar
• Hatzakis AE, Touloumi G, Pantazis N, et al. Cellular HIV-1 DNA load predicts HIV-RNA rebound and the outcome of highly active antiretroviral therapy. AIDS. 2004;18:2261–2267.
   PubMed Web of Science ®Google Scholar
• Parikh UM, Bacheler L, Koontz DI, Mellors JW. The K65R mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits bidirectional phenotypic antagonism with thymidine analog mutations. J ViroL 2006;80:4971–4977.
   PubMed Web of Science ®Google Scholar
• Wainberg MA, Brenner BG, Turner D. Changing patterns in the selection of viral mutations among patients receiv-ing nucleoside and nucleotide drug combinations directed against human immunodeficiency virus type 1 reverse tran-scriptase. Antimicrob Agents Chemother 2005;49: 1671–1678.
   PubMed Web of Science ®Google Scholar
• Wainberg MA, Turner D. Resistance issues with new nu-cleoside/nucleotide backbone options; J Acquir Immune Defic Syndr 2004;37:S36—S43.
   PubMed Web of Science ®Google Scholar